Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017168 (
gastroesophageal reflux disease
)
11,783
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Potassium (K+) ions are critical for the activation and catalytic cycle of the gastric H+, K(+)-ATPase, resulting in the secretion of hydrochloric acid into the parietal cell canaliculus. As both symptom, severity and esophageal mucosal damage in gastro-
esophageal reflux disease
(GERD) are related to the degree of acid exposure, K+ is a logical target for approaches to inhibit acid production. The probable K+ binding site on the gastric H+, K(+)-ATPase has recently been described and studies are elucidating how K+ activates the enzyme. K+ channels in the apical membrane of the parietal cell are implicated in the recycling of K+ and, to date, three potential K+ channels (KCNQ1, Kir2.1 and
Kir4.1
) have been identified. The channels represent theoretical sites for agents to control acid secretion but it will be difficult to develop selective blockers. An alternative strategy is to prevent K+ from activating gastric H+, K(+)-ATPase; the potassium-competitive acid blocker (P-CAB) class inhibits acid secretion by binding at or near the K+ binding site. Ongoing research is further defining the role of K+ in the functioning of the gastric H+, K(+)-ATPase, as well as determining the clinical utility of agents directed toward this important cation.
...
PMID:Role of potassium in acid secretion. 1614 29